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AbstrACt
Introduction National audits are used to monitor 
care quality and safety and are anticipated to reduce 
unexplained variations in quality by stimulating quality 
improvement (QI). However, variation within and 
between providers in the extent of engagement with 
national audits means that the potential for national 
audit data to inform QI is not being realised. This study 
will undertake a feasibility evaluation of QualDash, a 
quality dashboard designed to support clinical teams 
and managers to explore data from two national 
audits, the Myocardial Ischaemia National Audit Project 
(MINAP) and the Paediatric Intensive Care Audit Network 
(PICANet).
Methods and analysis Realist evaluation, which 
involves building, testing and refining theories of how 
an intervention works, provides an overall framework 
for this feasibility study. Realist hypotheses that 
describe how, in what contexts, and why QualDash is 
expected to provide benefit will be tested across five 
hospitals. A controlled interrupted time series analysis, 
using key MINAP and PICANet measures, will provide 
preliminary evidence of the impact of QualDash, while 
ethnographic observations and interviews over 12 
months will provide initial insight into contexts and 
mechanisms that lead to those impacts. Feasibility 
outcomes include the extent to which MINAP and 
PICANet data are used, data completeness in the audits, 
and the extent to which participants perceive QualDash 
to be useful and express the intention to continue using 
it after the study period.
Ethics and dissemination The study has been 
approved by the University of Leeds School of Healthcare 
Research Ethics Committee. Study results will provide 
an initial understanding of how, in what contexts, 
and why quality dashboards lead to improvements in 
care quality. These will be disseminated to academic 
audiences, study participants, hospital IT departments 
and national audits. If the results show a trial is feasible, 
we will disseminate the QualDash software through a 
stepped wedge cluster randomised trial.
IntroduCtIon
National clinical audits (NCAs), which 
provide comparative data on the perfor-
mance of healthcare providers, are one of 
the means by which health systems around 
the world monitor care quality and safety. In 
England, a programme of over 30 NCAs is 
managed by the Healthcare Quality Improve-
ment Partnership and all healthcare providers 
that contribute to delivery of the National 
Health Service (NHS) are required to partic-
ipate. Such audits are anticipated to reduce 
unexplained variations in healthcare quality 
by stimulating quality improvement (QI).1 2 
While there is evidence of positive impacts 
of NCAs,3–5 variation within and between 
providers in the extent to which they engage 
strengths and limitations of this study
 ► This study will assess the feasibility of a trial of 
QualDash, a quality dashboard; if a trial is feasi-
ble, the findings will be used to inform the design 
of the definitive trial, determining the components 
of QualDash to be preserved, appropriate outcome 
measures and the contexts in which the trial should 
be undertaken.
 ► Through a controlled interrupted time series (CITS) 
study and qualitative multi- site case study, the study 
will also provide an initial understanding of whether 
the use of a quality dashboard leads to quality im-
provement, how, in what contexts, and why.
 ► The study will contribute to understanding of how 
realist methods can contribute to feasibility studies 
and the design of trials.
 ► Issues of data quality may be a limitation of the CITS 
study; data completeness, and whether this chang-
es over the course of the study, will be assessed.
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Figure 1 Prototype of main dashboard view for the paediatric intensive care audit network (using simulated data).
with NCAs mean the potential for NCA data to inform QI 
is not being realised.6 7
Quality dashboards are a form of audit and feedback 
(A&F) that provide visualisations of audit data with the 
aim of informing QI efforts.8 Healthcare providers are 
increasingly using quality dashboards. For example, 
quality dashboard use has been reported in Canada,9 the 
UK10 and the Netherlands.11 While quality dashboards 
have been shown to have positive effects on some perfor-
mance indicators,9 empirical evidence regarding their 
impact remains limited.12
Qualdash
QualDash is an interactive web- based quality dashboard 
designed to support clinical teams and managers to 
explore data from two national audits, the Myocardial 
Ischaemia National Audit Project (MINAP) and the 
Paediatric Intensive Care Audit Network (PICANet), for 
the purpose of QI (figure 1). Information used to inform 
design of QualDash was collected through interviews 
with 50 clinicians and managers across five NHS Trusts 
(providers) and four healthcare commissioners, observa-
tions of meetings where audit data are discussed, a work-
shop with NCA suppliers, and two co- design workshops 
with clinicians and managers from one Trust.
The interviews revealed that use of NCA data is largely at 
the clinical team level, with more limited use at divisional 
and corporate (Board and sub- committees that report to 
the Board, such as Quality and Safety Committees) levels. 
At all levels, a key constraint in use of NCA data for QI is 
lack of access to timely data; there was consensus among 
interviewees that the data should not be more than 3 
months old. QualDash seeks to improve access to timely 
data, providing users with a means to visualise the data 
they collect for the NCAs, without having to wait for data 
to be returned to them from the NCAs. There is varia-
tion between Trusts in the extent to which NCA data are 
used, often related to resources, which in turn impacts on 
timeliness of data; Trusts that make greater use of NCA 
data tend to have local databases from which they can 
generate visualisations of the data (eg, bar charts) and 
audit support staff who have the time and skills to be able 
to generate such visualisations. In contrast, where such 
resources are not available, Trusts rely on the NCA annual 
reports, where data may be 15 months old (eg, one annual 
report published in June 2017 reported data from April 
2015 to March 2016). QualDash provides visualisations 
of key metrics, each metric being represented within a 
‘QualCard’ (figure 2), enabling Trusts to use NCA data 
for QI, regardless of existing resources. QualCards for 
MINAP and PICANet are listed in table 1; while there is 
only one set of QualCards for PICANet, for MINAP an 
additional QualCard is provided for teaching hospitals, as 
discussions with sites revealed that the metrics of interest 
are different between teaching hospitals and district 
general hospitals (DGHs). Sites are also able to create 
additional QualCards, to reflect local priorities.
To load new data into QualDash, NCA data are either 
extracted from the site’s database or downloaded from 
the NCA website, and then fed to a small script (written in 
R), which in turn updates the dashboard. Users can add 
new data as often as they want, but at a minimum they will 
load data into QualDash at the same time as uploading to 
the NCAs (typically every 3 months).
The benefits perceived from using QualDash may vary 
between sites, with under- resourced sites that previously 
made little use of NCA data for QI perceiving greater 
impact than those that already have the means to use NCA 
data for QI. There are also constraints on use of NCA data 
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Figure 2 Prototype of main dashboard view for the paediatric intensive care audit network with the mortality QualCard 
expanded (using simulated data).
Table 1 QualCards
Metric
MINAP—all sites Mortality
Door (arrival in accident and 
emergency) to angiogram time
Gold standard drugs on discharge
Referral for cardiac rehabilitation
Acute use of aspirin
MINAP—teaching 
hospital specific
Call (by patient/relative to emergency 
services) to balloon (percutaneous 
coronary intervention) time
PICANet—all sites Mortality
48 hours unplanned readmission
Bed days and accidental extubation
Specialty case mix
Data quality (number of records with a 
missing value)
Patient dependency
for QI that it may be difficult for QualDash to address. 
For example, in some Trusts, clinical team members 
perceive that relevant managers will not agree to provide 
the resources necessary for QI initiatives, which reduces 
motivation to engage with NCA data and may affect the 
extent to which QualDash is used. However, QualDash 
provides means for visualisations to be downloaded and 
incorporated into presentations and reports, which may 
support clinical teams in making a stronger case for QI 
initiatives. Another constraint on use of NCA data for 
QI relates to clinicians’ trust in the quality of the data. 
Interviews revealed variations across sites in processes for 
ensuring data quality. However, some interviewees also 
suggested that having the means to make more use of 
NCA data via QualDash would motivate them to improve 
their processes for ensuring data quality, although this 
will be dependent on local resources.
In this paper, we describe the methods for a realist feasi-
bility evaluation of QualDash. The study objectives are:
1. To develop an initial understanding of how, in what 
contexts, and why use of QualDash leads to QI; and
2. to assess the feasibility of conducting a trial of 
QualDash.
As no checklists exist for reporting of realist evaluation 
(RE) protocols, in presenting this protocol we draw on 
the RAMESES II reporting standards for REs13 (online 
supplementary file 1).
MEthods And AnAlysIs
study design
The use of theory is needed for design and evaluation 
of A&F interventions,14–16 and QI initiatives more gener-
ally.17–19 This project draws on RE, which involves building, 
testing and refining theories about how an intervention is 
supposed to work.20 These theories are expressed in the 
form of context, mechanism and outcome (CMO) config-
urations, where C+M=O, reflecting the realist under-
standing that it is recipients’ responses to the resources 
that an intervention provides (the intervention mecha-
nisms) that determine the impact of the intervention, and 
such responses are highly influenced by context.21 Conse-
quently, RE seeks to answer not only the question of ‘what 
works?’ but also ‘what works for whom, in what circum-
stances, and why?’22 It is concerned with both intended 
and unintended outcomes. RE is recommended for 
studying QI23 and has been used for studying the imple-
mentation and impact of large- scale QI programmes.24 
There is increasing interest in use of realist methods in 
feasibility evaluations.25–27
We have drawn on a range of sources to develop CMO 
configurations which describe how, in what contexts, and 
why use of QualDash is anticipated to lead to QI (see 
online supplementary file 2). Data generated from the 
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interviews, observations and workshops described above 
have been essential to this, as have discussions with the 
designers of QualDash (ME and RAR) who, drawing on 
their expertise in information visualisation, have their 
own literature- informed theories regarding why certain 
features of QualDash will provide benefit to users.28 29 
We have also drawn on substantive theories regarding 
how A&F lead to QI at the micro,30 31 meso32 and macro 
levels.33 34
Data collection is designed to enable testing of the 
CMO configurations. Outcome data, in the form of key 
MINAP and PICANet measures, will be collected and 
analysed in a controlled interrupted time series (CITS) 
study, while a multi- site case study35 will provide an initial 
understanding of the contexts and mechanisms that lead 
to those outcomes, as well as providing data on inter-
mediate outcomes, such as increased use of NCA data. 
A&F interventions, and QI interventions more generally, 
require longitudinal evaluation to allow sufficient time 
for staff to implement changes and incorporate them 
into their practice.36–38 Similarly, evaluation of health IT 
(HIT) should allow time for staff to integrate the tech-
nology into their practices and evolve those practices 
to take advantage of the functionality offered by the 
technology.39 Therefore, data will be collected over a 
12- month period, from August 2019.
Public and patient involvement
A Lay Advisory Group has been established, which has 
contributed to the design of QualDash by reviewing 
the topic guide for the interviews that were conducted, 
providing their perspective on the findings of the inter-
view study, and participating in the usability evaluation 
of QualDash. For the realist feasibility evaluation, they 
have provided advice on aspects to pay attention to when 
undertaking observations. They will contribute to analysis 
of a sample of the qualitative data, to provide a patient 
perspective. They will advise on dissemination of findings 
to relevant interest groups and will review outputs for 
comprehensibility.
setting/context
The feasibility study will be conducted in the five NHS 
acute Trusts in which the interview study that informed 
the design of QualDash was undertaken. Three Trusts 
are teaching hospitals that participate in both MINAP 
and PICANet and have been selected to ensure variation 
in key outcome measures (MINAP: 30- day mortality for 
patients hospitalised with ST- elevation myocardial infarc-
tion; PICANet: risk adjusted standardised mortality ratio). 
Two Trusts are DGHs that participate in MINAP but do 
not have a paediatric intensive care unit (PICU) and so 
do not participate in PICANet. These have been selected 
to ensure variation in the same key MINAP measure.
Multi-site case study
In the multi- site case study, data will be collected through 
ethnographic observation and interviews. Ethnographic 
methods have been argued as essential for studying 
implementation of QI interventions19 and introduction 
of HIT.40 Ethnography is well suited to RE because it 
involves observing phenomena in context, supporting 
understanding of how context influences the response 
to an intervention.41 We will follow the Biography of 
Artefacts approach,42 which is concerned with capturing 
how particular contexts and appropriations of a tech-
nology lead to different processes and generate different 
outcomes, a parallel to RE’s concern with contexts, mech-
anisms, and outcomes.43 It involves longitudinal ‘stra-
tegic ethnography’,42 where data collection is guided by 
a provisional understanding of the moments and locales 
in which a technology and associated practices evolve.43
Data collection
In the three teaching hospitals, we will undertake a 
minimum of 24 periods of observation per Trust, to be 
split across activities related to cardiology and the PICU, 
and in the two DGHs we will undertake a minimum of 12 
periods of observation per Trust, to be spent observing 
activities related to cardiology. Each period of observation 
will be a minimum of 4 hours (total n=384 hours). While 
researchers will return to each Trust monthly, to under-
stand how use of QualDash changes over time, more time 
will be spent in the first few months following the intro-
duction of QualDash, because this is when users are most 
likely to engage with and explore the affordances of Qual-
Dash and establish new practices around it, generating 
information with implications for system enhancement.43 
Observations will be scheduled to take place at different 
times of day and on different days of the week, to ensure 
the account of what is observed is as complete and repre-
sentative as possible.44
At each case site, an initial phase of general observation 
will provide an opportunity for researchers to become 
familiar with the setting and for those in the setting to 
become familiar with the presence of the researchers. 
Following a previous study of dashboards,10 observations 
will be undertaken in clinical areas to understand clinical 
teams’ working practices and capture ‘corridor commit-
tees’ where issues of quality and safety are discussed more 
informally.45 In the PICUs, initial observations will take 
place on the PICU, for example, with the researchers 
positioning themselves by the nurses’ station, as well as 
observing handovers, safety huddles and ward rounds. 
Because activities related to cardiology tend to be more 
dispersed across hospitals, researchers will first shadow 
clinical team members (consultant cardiologists and 
acute chest pain nurses) to determine where it is most 
appropriate to conduct subsequent observations. These 
initial observations will also be used to record general 
details of the setting that may influence QualDash use, 
such as staffing levels and availability of computers.
After this initial phase, observation will be guided by 
the CMO configurations under investigation. In addition 
to observing formal meetings where quality and safety 
are discussed, predominantly at ward level but also at 
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divisional and corporate level, observation will involve 
shadowing staff members as they undertake particular 
activities: collection and entry of NCA data, to see if and 
how this changes over time; accessing and interrogating 
NCA data, whether using QualDash or some other means; 
preparation of reports and/or presentations using NCA 
data, again whether using QualDash or some other 
means. Where visualisations from QualDash are incorpo-
rated into presentations and written reports, we will follow 
the path of those documents, to identify staff members 
who may not use QualDash directly but are receiving 
QualDash outputs. Attention will be paid to how, in what 
contexts and why QualDash and QualDash outputs are 
used or not, understood in the context of broader prac-
tices and use of other sources of information for moni-
toring care quality, and how this changes over time. We 
will also follow local QI initiatives, recording data on, for 
example, when and how the need for the QI initiative 
was identified, contextual factors that appear to support 
and constrain its introduction, how the impact of the QI 
initiative is monitored, and other contextual factors that 
appear to influence the metric that the QI initiative is 
targeting. Researchers will record observations in field-
notes, which will be written up in detail as soon after data 
collection as possible.
Brief interviews will be undertaken opportunistically 
during the course of conducting observations to clarify 
aspects of practice that are not immediately intelligible 
to an observer, with participant responses recorded in 
fieldnotes.46 As data collection progresses, longer semi- 
structured interviews will be used to discuss revisions 
to our CMO configurations. These will be undertaken 
using a particular approach from RE, referred to as the 
teacher–learner cycle, whereby the theories under inves-
tigation are made explicit to the interviewee so that 
the interviewee can use their experiences to refine the 
researcher’s understanding.47 Being concerned with the 
reasoning of intervention recipients, mechanisms are 
often not observable,21 so these longer interviews will 
also provide the opportunity to explore staff reasoning 
about QualDash. These longer interviews will be audio 
recorded and transcribed verbatim.
Logfiles are widely used to evaluate visualisation tools.48 
QualDash logfiles will record information about the user 
(job title and so on), data used (audit, year), overall 
time spent using QualDash, time spent interacting with 
different QualCards (including new QualCards that have 
been created), functionality used and whether QualDash 
visualisations were downloaded. In addition to providing 
data regarding extent of QualDash use, how QualDash 
is used and by whom, and how this changes over time, 
information from logfiles will be used to inform qualita-
tive data collection (eg, asking in interviews why partic-
ipants use particular QualCards and not others and the 
motivation behind the creation of new QualCards).
At the end of the data collection period, we will ask 
participants to complete a questionnaire based on the 
Technology Acceptance Model, using well- validated items 
that have been used in numerous evaluations of HIT,49 
including dashboards.50 This will provide participants’ 
perceptions of the usefulness of QualDash and data on 
whether they intend to continue using QualDash after 
the study period.
Analysis
An iterative approach to data collection and analysis will 
be taken, to enable: ongoing testing and refinement of 
the CMO configurations; gathering of further data in 
light of such revisions; and refinement of QualDash in 
response to participants’ feedback. Fieldnotes and inter-
view transcripts will be entered into NVivo 11. Narrative 
analysis will be undertaken to develop a ‘biography’ of 
QualDash, which will describe use of QualDash and its 
outputs by a range of stakeholders at different levels (clin-
ical team, divisional and corporate) and the intercon-
nections between them.10 Narrative analysis is consistent 
with a realist approach due to its emphasis on preserving 
connections within the data, thereby helping to under-
stand causality.51 This analysis will be supplemented with 
analysis of the logfiles and questionnaire data. Findings 
will be compared with the CMO configurations, to deter-
mine whether they support, refute or suggest a revision or 
addition to the CMO configurations.
CIts study
Interrupted time series studies provide a robust method of 
assessing the effect of an intervention and have been used 
to assess effectiveness of a variety of complex interven-
tions.52 In a CITS, the addition of a control group enhances 
causal inference because the presence of seasonal trends 
and other potential time- varying confounders can be 
assessed.53 Data will be collected across the five Trusts, 
with two control Trusts per intervention Trust, providing 
a total of 10 control Trusts. Control Trusts will be matched 
according to their size and outcomes pre intervention. 
Having more than one control site per intervention site 
increases power but, as the number of control sites per 
intervention site increases, quality of matching decreases. 
Therefore, we have chosen to have two control Trusts per 
intervention Trust to increase power while maintaining 
quality of the matching.
Given the study intention to determine the feasibility of 
and inform the design of a trial, a range of measures will 
be considered. Initially, we selected two process measures, 
one for MINAP and another for PICANet. For MINAP, 
we selected the composite process measure cumulative 
missed opportunities for care (CMOC). This has nine 
components (pre- hospital ECG, acute use of aspirin, 
timely perfusion, referral for cardiac rehabilitation and 
prescription at hospital discharge of what are consid-
ered to be the gold standard drugs—aspirin, thienopyr-
idine inhibitor, angiotensin converting enzyme inhibitor, 
β-Hydroxy β-methylglutaryl- CoA (HMG- CoA) reductase 
inhibitor and beta blockers) and is inversely associated 
with mortality.54 As some of these components, such as 
pre- hospital ECG, are outside the direct control of the 
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Trust, we will also explore the impact of QualDash on the 
individual measures that make up CMOC. On the basis of 
the measures that cardiology clinicians described in the 
interviews as being important for measuring care quality, 
we will also look at the percentage of patients who receive 
an angiogram within 72 hours from first admission to 
hospital, which is part of the Best Practice Tariff financial 
incentive scheme, and, for those hospitals that provide 
percutaneous coronary intervention (PCI), the propor-
tion of patients who have a door- to- balloon time (the time 
from arrival at the hospital to PCI) of less than 60 min. 
Our CMO configurations (online supplementary file 2) 
suggest improvement will be seen in measures if: clinical 
teams perceive them as being important indicators of care 
and/or they relate to financial incentives; performance is 
not in line with expectations; they perceive the measure 
as being within their control; and the team is resourced 
to introduce QI initiatives in relation to these measures.
For PICANet, we selected use of non- invasive ventila-
tion first for patients requiring ventilation, which has 
been shown to be associated with reduced mortality.55 
However, this was not raised as an area of concern in our 
interviews with PICU clinicians. On the basis of this and 
two additional considerations—it would require loading 
additional data into QualDash which would reduce the 
performance of QualDash in terms of speed and it requires 
computation of the data, while the focus of QualDash is 
on visualising the data—a QualCard has not been created 
for this metric. Therefore, while we will still include this 
measure in the CITS, we do not hypothesise that it will 
change, unless other sources of information, such as the 
PICANet annual report, draw a PICU team’s attention to 
it. However, accidental extubation and unplanned read-
mission within 48 hours were identified in our interviews 
with PICU clinicians as being important indicators of care 
quality, so we will include these two measures in the CITS. 
On the basis of our CMO configurations (online supple-
mentary file 2), we would expect to see an improvement 
in these measures in sites where performance is not in 
line with expectations, if the team is resourced to intro-
duce QI initiatives in relation to these measures.
Sample size considerations
A CITS study requires data for a minimum of three 
time points pre- intervention and three time points 
post- intervention and must also allow for any seasonal 
effect on the outcomes.56 Monthly data will be obtained 
for 24 months pre- intervention and 12 months post- 
intervention. Consequently, for each intervention Trust, 
there will be 72 data points prior to introduction (24 for 
the intervention Trust and 48 for the control Trusts) and 
36 data points post intervention (12 for the intervention 
Trust and 24 for the control Trusts). Sample size calcula-
tions were undertaken based on our two initial measures, 
CMOC for MINAP and use of non- invasive ventilation 
first for patients requiring ventilation for PICANet; full 
details are provided in online supplementary file 3.
Analysis
Monthly MINAP and PICANet data will be extracted to 
spreadsheets for analysis with R software.57 For both NCAs, 
each outcome will be regressed on time and the interven-
tion. The time component will include a seasonal effect 
(quarterly effect) and will allow for a (linear) time trend. 
To account for clustering of monthly observations within 
hospitals, a random intercept will be fitted, although a 
fixed effect for hospital as a sensitivity analysis will be 
explored. Although the intervention is abrupt, its impact 
may well be ‘phased in’ over a few months, perhaps three. 
The timing of the bedding in of the intervention will be 
reported from the multi- site case study. Then a partial 
effect can be considered for this period with the interac-
tion effect stepping up in a linear fashion.
The results of the CITS analysis will be incorporated 
into the biography of QualDash, the analysis of the data 
from the multi- site case study describing how contextual 
factors shape the evolution of practices around QualDash 
and how this leads to the resulting outcome pattern.
trial feasibility assessment and design
Our trial progression criteria are: (1) the number of 
people who engage with either MINAP or PICANet 
data (via QualDash or some other means) is the same 
or higher than the number of people who engaged with 
either MINAP or PICANet data prior to QualDash’s intro-
duction; (2) data completeness in the national audit 
improves or remains the same; (3) 50% or more of partic-
ipants in the questionnaire survey perceive QualDash to 
be useful and express the intention to continue using it 
after the study period. Criteria (1) and (2) are concerned 
with ensuring the intervention does not have unintended 
negative consequences which would affect success of the 
intervention. Criterion (2) is also concerned with feasi-
bility of outcome assessment. Criterion (3) is concerned 
with acceptability and uptake of the intervention, and 
therefore has implications for recruitment to a trial, as 
well as being concerned with participants’ perceptions 
of the impact of QualDash on care. While not formally 
assessed as part of the progression criteria, the impact of 
QualDash on care as identified in the CITS will be consid-
ered in determining whether a future trial is justified. A 
traffic light system will be used to determine if a trial is 
feasible (green), feasible with modifications to QualDash 
(amber), or not feasible (red).58 59
If the results show a trial of QualDash is feasible, we 
will design a stepped wedge cluster randomised trial. Data 
from the CITS will be used to inform the selection of NCAs 
to be included in the trial (MINAP and/or PICANet) and 
will provide information about variability of outcomes 
and about how long a trial intervention period would 
need to be. Findings from the multi- site case study will 
be used to inform the selection of categories of user to 
be included in the trial and, associated with this, the 
level of randomisation (Trust, hospital or ward). Using 
the understanding of the relationship between contexts, 
mechanisms and outcomes provided by the study, we will 
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identify QualDash components associated with mech-
anisms that produce the desired outcomes in order for 
them to be preserved in the trial, while other components 
can be adapted to suit the local context.
EthICs And dIssEMInAtIon
Written consent will be obtained from participants for 
interviews and for meeting observations.
Study results will provide initial understanding of 
how and in what contexts quality dashboards may lead 
to improvements in care quality. We will disseminate 
these results to academic audiences, study participants, 
hospital IT departments and NCAs. If we progress to a 
trial, in addition to providing further understanding of 
the impact of quality dashboards on care quality, this will 
result in wider dissemination of the QualDash software.
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